Research Highlights
► Within
this randomized trial a statistical benefit was seen with primary
surgery among patients with less than 5 cm of upper abdominal
disease
(HR 0.64).
► Across different countries in this study there was
significant
heterogeneity of the benefit of primary cytoreductive
surgery.
refers to:
EORTC Newsletter
Results of the EORTC 55971 trial: Neoadjuvant
chemotherapy
followed by interval debulking surgery is not inferior to
primary
debulking surgery followed by chemotherapy as a treatment
option for
patients with stage IIIC or IV ovarian carcinoma
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.